JP2005536449A - グルタチオンおよび第2相解毒酵素による酸化ストレス障害の予防および治療 - Google Patents
グルタチオンおよび第2相解毒酵素による酸化ストレス障害の予防および治療 Download PDFInfo
- Publication number
- JP2005536449A JP2005536449A JP2003552246A JP2003552246A JP2005536449A JP 2005536449 A JP2005536449 A JP 2005536449A JP 2003552246 A JP2003552246 A JP 2003552246A JP 2003552246 A JP2003552246 A JP 2003552246A JP 2005536449 A JP2005536449 A JP 2005536449A
- Authority
- JP
- Japan
- Prior art keywords
- methyltransferase
- glutathione
- synthetase
- phase
- sulforaphane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 99
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 66
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 66
- 229960003180 glutathione Drugs 0.000 title claims abstract description 52
- 230000036542 oxidative stress Effects 0.000 title claims abstract description 45
- 208000013200 Stress disease Diseases 0.000 title claims abstract description 28
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 238000001784 detoxification Methods 0.000 title claims description 11
- 230000002265 prevention Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 230000037041 intracellular level Effects 0.000 claims abstract description 27
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical group CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims description 148
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims description 73
- 229960005559 sulforaphane Drugs 0.000 claims description 73
- 235000015487 sulforaphane Nutrition 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 claims description 22
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 claims description 22
- 150000002540 isothiocyanates Chemical class 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 13
- 108010070675 Glutathione transferase Proteins 0.000 claims description 12
- 102000016761 Haem oxygenases Human genes 0.000 claims description 12
- 108050006318 Haem oxygenases Proteins 0.000 claims description 12
- 125000004383 glucosinolate group Chemical group 0.000 claims description 12
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 11
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims description 11
- 102000016354 Glucuronosyltransferase Human genes 0.000 claims description 11
- 108010092364 Glucuronosyltransferase Proteins 0.000 claims description 11
- 101710202061 N-acetyltransferase Proteins 0.000 claims description 11
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 claims description 10
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 claims description 10
- 108090001033 Sulfotransferases Proteins 0.000 claims description 10
- 102000004896 Sulfotransferases Human genes 0.000 claims description 10
- 108090000958 Thiopurine S-methyltransferases Proteins 0.000 claims description 10
- 102000004377 Thiopurine S-methyltransferases Human genes 0.000 claims description 10
- 108010000523 phenol O-methyltransferase Proteins 0.000 claims description 10
- 108010011661 thiol S-methyltransferase Proteins 0.000 claims description 10
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 claims description 9
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 claims description 9
- 102000016938 Catalase Human genes 0.000 claims description 9
- 108010053835 Catalase Proteins 0.000 claims description 9
- 102000005870 Coenzyme A Ligases Human genes 0.000 claims description 9
- 108010036164 Glutathione synthase Proteins 0.000 claims description 9
- 102100034294 Glutathione synthetase Human genes 0.000 claims description 9
- 108010030471 Histamine N-methyltransferase Proteins 0.000 claims description 9
- 102100029076 Histamine N-methyltransferase Human genes 0.000 claims description 9
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 claims description 9
- 108010088865 Nicotinamide N-Methyltransferase Proteins 0.000 claims description 9
- 102000009063 Nicotinamide N-methyltransferase Human genes 0.000 claims description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 9
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 8
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 8
- 101710102974 O-acetyl transferase Proteins 0.000 claims description 8
- 201000007737 Retinal degeneration Diseases 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 8
- 230000004258 retinal degeneration Effects 0.000 claims description 8
- 241000720950 Gluta Species 0.000 claims description 7
- 102000055027 Protein Methyltransferases Human genes 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 4
- 102000004316 Oxidoreductases Human genes 0.000 claims 4
- 108090000854 Oxidoreductases Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 74
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 71
- 239000011652 vitamin K3 Substances 0.000 description 35
- 235000012711 vitamin K3 Nutrition 0.000 description 35
- 229940041603 vitamin k 3 Drugs 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000002676 xenobiotic agent Substances 0.000 description 29
- 239000007800 oxidant agent Substances 0.000 description 26
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 24
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 230000001988 toxicity Effects 0.000 description 18
- 231100000419 toxicity Toxicity 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000021615 conjugation Effects 0.000 description 15
- 230000002034 xenobiotic effect Effects 0.000 description 15
- 239000003963 antioxidant agent Substances 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000001590 oxidative effect Effects 0.000 description 13
- -1 sulfur ions Chemical class 0.000 description 13
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 108010063907 Glutathione Reductase Proteins 0.000 description 8
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 8
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000007069 methylation reaction Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000004357 Transferases Human genes 0.000 description 6
- 108090000992 Transferases Proteins 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000006640 acetylation reaction Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QZRFYFSUCVLHML-IUCAKERBSA-N (1s,3s)-1-(isothiocyanatomethyl)-3-methylsulfonylcyclohexane Chemical compound CS(=O)(=O)[C@H]1CCC[C@H](CN=C=S)C1 QZRFYFSUCVLHML-IUCAKERBSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- BQYLCVLIDSFGNX-UHFFFAOYSA-N 6-isothiocyanatohexan-2-ol Chemical compound CC(O)CCCCN=C=S BQYLCVLIDSFGNX-UHFFFAOYSA-N 0.000 description 2
- KXJVOLXLYNDZME-UHFFFAOYSA-N 6-isothiocyanatohexan-2-one Chemical compound CC(=O)CCCCN=C=S KXJVOLXLYNDZME-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 2
- 229960004419 dimethyl fumarate Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000000887 face Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000023611 glucuronidation Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BSAIUMLZVGUGKX-UHFFFAOYSA-N non-2-enal Chemical compound CCCCCCC=CC=O BSAIUMLZVGUGKX-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 2
- 229950008687 oltipraz Drugs 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 231100000760 phototoxic Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SIQPZGADPPVYAP-UHFFFAOYSA-N 1-isothiocyanato-5-methylsulfonylpentane Chemical compound CS(=O)(=O)CCCCCN=C=S SIQPZGADPPVYAP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000017163 Acephala Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical compound [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000005298 Iron-Sulfur Proteins Human genes 0.000 description 1
- 108010081409 Iron-Sulfur Proteins Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000700207 Mus macedonicus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 101710095135 NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011419 induction treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000012314 multivariate regression analysis Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
本発明は概して動物細胞におけるグルタチオンの細胞内レベルまたは少なくとも1つの第2相解毒酵素の細胞内レベルを上昇させる、医薬的有効量の化合物を投与することにより酸化ストレスを治療する分野に関する。本発明はまた動物細胞におけるグルタチオンの細胞内レベルまたは少なくとも1つの第2相解毒酵素の細胞内レベルを上昇させる、医薬的有効量の化合物を投与することにより被検対象を酸化ストレスから保護する分野にも関する。本発明はまた酸化ストレス障害の治療に有用な医薬用組成物にも関する。
酸化ストレス障害の治療に有用な本発明の作用物質および医薬的に許容される担体または賦形剤を含む本発明の医薬用組成物が提供される。このような作用物質を人工的に合成するかまたは天然の供給源から入手することができる。前記作用物質が天然の供給源から入手される場合、このような作用物質を必ずしも医薬的に許容される担体または賦形剤と組み合わせる必要はない。天然の供給源の実例としてはacephala、alboglabra、botrytis、costata、gemmifera、gongylodes、italica、medullosa、palmifolia、ramosa、sabauda、sabellicaおよびselensiaからなる変種の群から選択されるBrassica oleracea種子である。さらなる天然の供給源の実例はアブラナ科植物のスプラウト(新芽)である。
本発明の作用物質の有効量を実験的に決定でき、そして純粋な形態で、またはこのような形態が存在する場合、医薬的に許容される塩、エステルまたはプロドラッグの形態で用いることができることは当業者に理解されよう。神経学的障害の治療を必要とする被検対象に、作用物質を1つまたはそれ以上の医薬的に許容される賦形剤と組み合わせた医薬用組成物として投与することができる。ヒト患者に投与する場合、主治医による十分な医学的判断の範囲内で本発明の作用物質または組成物の一日用量が決定されることは理解されよう。いずれかの特定の患者に関する特定の治療有効量レベルは種々の因子に依存する。達成される細胞応答の型および程度;用いた特定の作用物質または組成物の活性;用いた特定の作用物質または組成物;患者の年齢、体重、一般的な健康状態、性別および食事;投与時間、投与経路、および作用物質の排泄速度;治療期間;特定の作用物質と組み合わせて、または同時に用いられる薬物;並びに医学の分野で周知の因子等。例えば、望ましい治療効果を達成するのに必要とされるレベルよりも低いレベルで作用物質の投与量で始め、そして望ましい効果が達成されるまで徐々に用量を増加させることは十分に当業者の範囲内である。
[化学物質]tert−ブチルハイドロペルオキサイド、3−モルフォリノシドノニミン(SIN−1)、メナジオン亜硫酸ナトリウム(メナジオン)、および臭化3−[4,5−ジメイルチアゾール−2−イル]−2,5−ジフェニルテトラゾリウム(MTT)、オールトランスレチナール、をSigma(St.Louis,ミズーリ州)から購入した。4−ヒドロキシノン−2−エナールをCayman Chemical Co.(Ann Arbor、ミシガン州)から入手し、そして合成スルフォラファン[1−イソチオシナト−(4R,S)−(メチルスルフィニル)ブタン]をLKT Laboratories(St.Paul、ミネソタ州)から入手した。
全ての実験を96ウェルマイクロタイタープレートで実施した。ARPE−19およびHaCaT細胞をウェルあたり10,000セルで播種し、そして24時間成長させた後、スルフォラファンを添加し、一方L1210細胞(5,000セル/ウェル)はスルフォラファン処理の前にインキュベートしなかった。ジメチルスルフォキシド中スルフォラファン(5mM)溶液を同種の培養培地で希釈して最終誘導物質濃度0.16から5.0μMを提供した。最終DMSO濃度は≦0.1(容量)%であった。
[ヒト網膜色素上皮細胞に対するメナジオン毒性およびスルフォラファンによる保護の定量的測定]
96ウェルマイクロタイタープレートで成長させたARPE−19細胞に関する酸化剤毒性およびスルフォラファンによる保護の定量的決定のための標準化され、高度に再現性のある系が開発された。0から5μMの濃度のスルフォラファンとの24時間の事前のインキュベーションの、0から250μM メナジオンに2時間暴露したARPE−19細胞の生存性に及ぼす保護効果を図1に説明し、これは漸増濃度のメナジオンへの細胞毒性のS字型依存性を示す(部分的細胞死滅化としてプロット、すなわち影響を受けた分画=fa)。メナジオンの最高濃度ではほとんどの細胞が生存していないが、スルフォラファンでの前処理によりかなりの分画の細胞を酸化による死に対して保護した。写真に示すように(図1)、試験した濃度範囲にわたって、酸化剤メナジオンの濃度が上昇するにつれて細胞生存性は低減し、そしてスルフォラファンの濃度が上昇するにつれて増加した。
[スルフォラファンによるメナジオン毒性に対するARPE−19の保護およびグルタチオンレベルの上昇およびキノンリダクターゼ特異的活性の間の相関性]
メナジオン毒性に関してDm値を決定するために前記で用いた条件と同一の条件下で、0から5.0μM スルフォラファンで24時間処理したARPE−19細胞のサイトゾルにおけるQRの特異活性およびGSHの濃度を測定した。予想されたとおり、第2相誘導の双方の指標は漸増濃度のスルフォラファンへの暴露と共に上昇した(図2)。応答はスルフォラファン濃度と直線的に相関した(各々r2=0.995および0.935)。さらに重要なことに、多変数回帰分析によりスルフォラファン濃度とQR活性、GSHレベルおよびDm値の間に高度な相関性が示された(各々p=0.0095、0.0004、0.0038)。従って、メナジオン毒性に対してスルフォラファンにより与えられた保護の程度と、QR活性およびGSHレベルの上昇との間に高度に有意な定量的な関連性があり、これはこれらの変数における変化が原因として関係していることが強く示唆された。
[スルフォラファンはメナジオン酸化ストレスに対する抗酸化剤保護の延長を提供する]
スルフォラファンはその他のイソチオシアネートと同様に、通常の酸化/還元反応には関与せず、その抗酸化メカニズムは間接的、恐らく第2相タンパク質の誘導による可能性が高い。結果的にスルフォラファンの保護効果は触媒性であり、そして誘導物質を除去した後、数日間持続する(同族タンパク質の半減期に相関する)可能性があり、ラジカルクエンチング反応において化学量論的に消費される直接的抗酸化剤(例えばアスコルビン酸、トコフェロール)とは異なっている。従って、ARPE−19細胞を2種の濃度のスルフォラファン(0.625および2.5μM)と24時間処理し、次いでウシ胎仔血清不含培地中さらに96時間インキュベートした(細胞成長の複雑化および特定の生化学的指標に及ぼす細胞集団増加の影響を区別する困難を最低限にするために)。スルフォラファン暴露の直後およびその後24時間間隔でメナジオン毒性(2時間暴露)に関して同一プレートの3検体ずつのセットを評価した。コントロール細胞のメナジオンに関する半有効濃度(Dm)は66.8μMであり、そして0.625および2.5μMのスルフォラファンで処理した細胞に関するDm値は、各々69.2および94.5μMであった。コントロール細胞抵抗性は48時間変化しないままであったが、一方スルフォラファンで処理した細胞のメナジオン毒性に対する抵抗性は、この期間中上昇し続け、そして次に続く48時間にわたって低下し、最終的にコントロール細胞レベルに近づいた(図3)。
[スルフォラファンによるtert−ブチルハイドロペルオキサイド、過酸化亜硝酸、および4−ヒドロキシノネナールの酸化ストレスに対するスルフォラファンによるARPE−19細胞の保護]
メナジオンの作用メカニズムとは異なる作用メカニズムを有するその他の酸化剤に対しても、一連の濃度のスルフォラファン(0、0.625、1.25および2.5mM)でのARPE−19細胞の処理により保護が提供された。従って、tert−ブチルハイドロペルオキサイド(0.5から1.0mMで16時間)、過酸化亜硝酸(SIN−1から作製される、0.25から4.0mMで2時間)、および4−ヒドロキシノネナール(1.56から25μMで4時間)の細胞毒性もまたスルフォラファンでの処理により有意に改善された。この保護はメナジオンに対する保護と同様に酸化剤およびスルフォラファンの双方の濃度に依存した(図5および表1)。
[酸化ストレスに対するヒトケラチノサイト(HaCaT)およびネズミ白血病(L1210)細胞の保護]
第2相誘導による保護の一般性を試験するために、tert−ブチルハイドロペルオキサイドおよびメナジオンの各々ヒトケラチノサイト(HaCaT)およびマウス白血病(L1210)細胞に対する毒性に及ぼすスルフォラファンでの24時間の処理の効果の分析を行なった(図6)。興味深いことに、これらの細胞系における双方の酸化剤に関する半有効性プロットの勾配は0.8から1.2の範囲であり、これはこれらの細胞系の細胞死に寄与する過程での有意な協同性の欠如を示している。これは同一の酸化剤のARPE−19細胞に及ぼす効果とは全く異なっている(表1)。従って致死過程間の協同性は細胞系に依存すると思われる。それにも関わらず形質転換されていないヒトケラチノサイト細胞系において、および高度な腫瘍性のネズミ白血病細胞系において観察された実質的な保護により、スルフォラファンにより提供される保護はより一般的な現象であり、網膜上皮色素細胞に限定されないことが示される。
[オールトランスレチナールおよび365nmでの光暴露により誘導された光酸化攻撃に対するヒトARPE細胞の保護]
オールトランスレチナールおよび光暴露により媒介される光毒性損傷に対するスルフォラファンの保護効果を試験するために、0から5μM スルフォラファンと共に24時間インキュベートした後、細胞を0から100μM オールトランスレチナールと2時間、および365nmでの光暴露で20分間、細胞を処理した。表2は細胞生存性が光酸化剤およびスルフォラファンの濃度の関数であることを示している。例えば細胞を50μM オールトランスレチナールで処理した場合、細胞生存性(コントロールの9.4、11.7、15.2および27,4%)はスルフォラファン濃度(各々0.0、1.25、2.5および5.0μM)に依存した。
Claims (21)
- 酸化ストレス障害の治療を必要とする被検対象の治療方法であって、前記被検対象の疾患組織においてグルタチオンの細胞内レベルまたは少なくとも1つの第2相解毒酵素の細胞内レベルを上昇させる医薬的有効量の化合物を投与することを含む方法。
- 前記化合物がイソチオシアネートおよびグルコシノレートからなる群から選択される請求項1の方法。
- 前記イソチオシアネートがスルフォラファンである請求項2の方法。
- 前記酸化ストレス障害が網膜変性、アルツハイマー病および加齢からなる群から選択される請求項1の方法。
- 前記第2相解毒酵素が、UDP−グルクロノシルトランスフェラーゼ、スルホトランスフェラーゼ、フェノール−O−メチルトランスフェラーゼ、カテコール−O−メチルトランスフェラーゼ、ヒスタミンN−メチルトランスフェラーゼ、ニコチンアミドN−メチルトランスフェラーゼ、チオプリンメチルトランスフェラーゼ、チオールメチルトランスフェラーゼ、N−アセチルトランスフェラーゼ、O−アセチルトランスフェラーゼ、アシル−CoAシンテターゼ、アシル−CoA:アミノ酸N−アシルトランスフェラーゼ、アミノアシル−tRNAシンテターゼ、グルタチオンシンテターゼ、γグルタミルシステインシンテターゼ、グルタチオンS−トランスフェラーゼ、キノンリダクターゼ、ヘムオキシゲナーゼ、ロダネーゼ、グルタチオンリダクターゼ、グルタチオンペルオキシダーゼ、カタラーゼおよびスーパーオキサイドジスムターゼからなる群から選択される請求項1の方法。
- 被検対象を酸化ストレス障害から保護する方法であって、被検対象の疾患組織においてグルタチオンの細胞内レベルまたは少なくとも1つの第2相解毒酵素の細胞内レベルを上昇させる医薬的有効量の化合物を前記被検対象に投与することを含む方法。
- 前記化合物がイソチオシアネートおよびグルコシノレートからなる群から選択される請求項6の方法。
- 前記イソチオシアネートがスルフォラファンである請求項7の方法。
- 前記酸化ストレス障害が、網膜変性、アルツハイマー病および加齢からなる群から選択される請求項6の方法。
- 前記第2相解毒酵素が、UDP−グルクロノシルトランスフェラーゼ、スルホトランスフェラーゼ、フェノール−O−メチルトランスフェラーゼ、カテコール−O−メチルトランスフェラーゼ、ヒスタミンN−メチルトランスフェラーゼ、ニコチンアミドN−メチルトランスフェラーゼ、チオプリンメチルトランスフェラーゼ、チオールメチルトランスフェラーゼ、N−アセチルトランスフェラーゼ、O−アセチルトランスフェラーゼ、アシル−CoAシンテターゼ、アシル−CoA:アミノ酸N−アシルトランスフェラーゼ、アミノアシル−tRNAシンテターゼ、グルタチオンシンテターゼ、γグルタミルシステインシンテターゼ、グルタチオンS−トランスフェラーゼ、キノンリダクターゼ、ヘムオキシゲナーゼ、ロダネーゼ、グルタチオンリダクターゼ、グルタチオンペルオキシダーゼ、カタラーゼおよびスーパーオキサイドジスムターゼからなる群から選択される請求項6の方法。
- 被検対象を眼の変性から保護する方法であって、被検対象の疾患組織においてグルタチオンの細胞内レベルまたは少なくとも1つの第2相解毒酵素の細胞内レベルを上昇させる医薬的有効量の化合物を前記被検対象に投与することを含む方法。
- 前記化合物がイソチオシアネートおよびグルコシノレートからなる群から選択される請求項11の方法。
- 前記イソチオシアネートがスルフォラファンである請求項12の方法。
- 前記酸化ストレス障害が網膜変性、アルツハイマー病および加齢からなる群から選択される請求項11の方法。
- 前記第2相解毒酵素が、UDP−グルクロノシルトランスフェラーゼ、スルホトランスフェラーゼ、フェノール−O−メチルトランスフェラーゼ、カテコール−O−メチルトランスフェラーゼ、ヒスタミンN−メチルトランスフェラーゼ、ニコチンアミドN−メチルトランスフェラーゼ、チオプリンメチルトランスフェラーゼ、チオールメチルトランスフェラーゼ、N−アセチルトランスフェラーゼ、O−アセチルトランスフェラーゼ、アシル−CoAシンテターゼ、アシル−CoA:アミノ酸N−アシルトランスフェラーゼ、アミノアシル−tRNAシンテターゼ、グルタチオンシンテターゼ、γグルタミルシステインシンテターゼ、グルタチオンS−トランスフェラーゼ、キノンリダクターゼ、ヘムオキシゲナーゼ、ロダネーゼ、グルタチオンリダクターゼ、グルタチオンペルオキシダーゼ、カタラーゼおよびスーパーオキサイドジスムターゼからなる群から選択される請求項11の方法。
- 前記化合物がイソチオシアネートおよびグルコシノレートからなる群から選択される請求項21の方法。
- 前記イソチオシアネートがスルフォラファンである請求項24の方法。
- 前記第2相解毒酵素が、UDP−グルクロノシルトランスフェラーゼ、スルホトランスフェラーゼ、フェノール−O−メチルトランスフェラーゼ、カテコール−O−メチルトランスフェラーゼ、ヒスタミンN−メチルトランスフェラーゼ、ニコチンアミドN−メチルトランスフェラーゼ、チオプリンメチルトランスフェラーゼ、チオールメチルトランスフェラーゼ、N−アセチルトランスフェラーゼ、O−アセチルトランスフェラーゼ、アシル−CoAシンテターゼ、アシル−CoA:アミノ酸N−アシルトランスフェラーゼ、アミノアシル−tRNAシンテターゼ、グルタチオンシンテターゼ、γグルタミルシステインシンテターゼ、グルタチオンS−トランスフェラーゼ、キノンリダクターゼ、ヘムオキシゲナーゼ、ロダネーゼ、グルタチオンリダクターゼ、グルタチオンペルオキシダーゼ、カタラーゼおよびスーパーオキサイドジスムターゼからなる群から選択される請求項21の方法。
- 医薬用賦形剤および(i)グルタチオンの細胞内レベル、または(ii)少なくとも1つの第2相解毒酵素の細胞内レベルのうちの少なくとも1つを増加させる医薬的有効量の作用物質を含む組成物。
- 前記作用物質がイソチオシアネートおよびグルコシノレートからなる群から選択される請求項27の組成物。
- 前記イソチオシアネートがスルフォラファンである請求項28の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34027301P | 2001-12-18 | 2001-12-18 | |
PCT/US2002/040457 WO2003051313A2 (en) | 2001-12-18 | 2002-12-18 | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005536449A true JP2005536449A (ja) | 2005-12-02 |
Family
ID=23332637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003552246A Pending JP2005536449A (ja) | 2001-12-18 | 2002-12-18 | グルタチオンおよび第2相解毒酵素による酸化ストレス障害の予防および治療 |
Country Status (9)
Country | Link |
---|---|
US (3) | US7407986B2 (ja) |
EP (3) | EP2138170A3 (ja) |
JP (1) | JP2005536449A (ja) |
CN (1) | CN1620304B (ja) |
AT (1) | ATE445405T1 (ja) |
AU (1) | AU2002357311A1 (ja) |
CA (1) | CA2470583C (ja) |
DE (1) | DE60234052D1 (ja) |
WO (1) | WO2003051313A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008016095A1 (fr) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
WO2010084661A1 (ja) * | 2009-01-23 | 2010-07-29 | 金印株式会社 | イソチオシアネート類含有組成物、食品、食品素材、医薬品、化粧品および日用品雑貨類 |
JP2011518860A (ja) * | 2008-04-29 | 2011-06-30 | ファーネクスト | ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物 |
JP2014532703A (ja) * | 2011-10-31 | 2014-12-08 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 自閉症の処置のための方法および組成物 |
WO2015002279A1 (ja) * | 2013-07-03 | 2015-01-08 | 味の素株式会社 | グルタチオン生成促進用組成物 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015913A (en) | 1996-09-06 | 2000-01-18 | Mars, Incorporated | Method for producing fat and/or solids from cocoa beans |
DE60234052D1 (de) * | 2001-12-18 | 2009-11-26 | Brassica Foundation For Chemop | Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen |
AU2004308919B2 (en) * | 2003-12-22 | 2009-11-12 | Alcon, Inc. | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
WO2005063249A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
JP5133064B2 (ja) * | 2005-01-05 | 2013-01-30 | 國防教育研究基金会 | ウリジン2リン酸(udp)−グルクロン酸転移酵素2b(ugt2b)の抑制剤及び促進剤 |
US7744937B2 (en) | 2005-08-09 | 2010-06-29 | Kraft Foods Global Brands Llc | Chemoprotectants from crucifer seeds and sprouts |
JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
US20080311276A1 (en) * | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Production of Glucosinolates from Agricultural By-Products & Waste |
US20080311192A1 (en) * | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Enteric-Coated Glucosinolates And Beta-Thioglucosidases |
US20090324522A1 (en) * | 2008-06-18 | 2009-12-31 | Western Holdings, Llc | Skin protectant compositions |
CA2729605A1 (en) * | 2008-06-30 | 2010-01-14 | The Johns Hopkins University | Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa |
GB0811992D0 (en) * | 2008-07-01 | 2008-08-06 | Mithen Richard | Treatment |
EP2616061A4 (en) * | 2010-09-17 | 2014-03-12 | Brassica Prot Products Llc | GLUCOSINOLATE TREATMENT FORMULATIONS |
US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
US10925934B2 (en) | 2011-02-22 | 2021-02-23 | Caudill Seed and Warehouse Co., Inc. | Spray dried myrosinase and use to produce isothiocynates |
EP2601946A1 (en) | 2011-12-06 | 2013-06-12 | Pécsi Tudomànyegyetem | Treatment and prevention of diseases related to oxidative stress |
US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
WO2014018874A1 (en) | 2012-07-26 | 2014-01-30 | The William M. Yarbrough Foundation | Method for treating skin cancer |
US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
ITMI20121774A1 (it) * | 2012-10-19 | 2014-04-20 | Placido Bramanti | Uso di un fitochimico bioattivato come agente neuroprotettivo per la prevenzione ed il trattamento di patologie correlate al sistema nervoso |
CA3153463A1 (en) | 2012-10-29 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
WO2014100361A1 (en) * | 2012-12-19 | 2014-06-26 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
KR20230117644A (ko) | 2016-11-17 | 2023-08-08 | 레노비온, 아이엔씨. | 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료 |
MX2020005087A (es) | 2017-11-17 | 2020-08-13 | Renovion Inc | Composiciones de acido ascorbico estables y metodos de uso de las mismas. |
US10441578B2 (en) * | 2018-01-19 | 2019-10-15 | Louis Habash | Altering expression level of glutathione S-transferase genes by treating a human subject with a nitroxide |
WO2024050405A1 (en) * | 2022-08-30 | 2024-03-07 | Green Shawn J | Compositions and methods for improving nitric oxide levels in intraoral, nasal and/or nasopharyngeal area |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US36784A (en) | 1862-10-28 | Improvement in separators and smut-mach ines | ||
US5747459A (en) * | 1991-02-04 | 1998-05-05 | Nestec, Ltd. | Method for insuring adequate intracellular glutathione in tissue |
IT1256178B (it) * | 1992-11-30 | 1995-11-29 | Lorenzo Ferrari | Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
US5411986A (en) | 1993-03-12 | 1995-05-02 | The Johns Hopkins University | Chemoprotective isothiocyanates |
AU7596994A (en) | 1993-11-01 | 1995-05-18 | Free Radical Sciences, Inc. | Methods and compositions for retarding the aging process |
FR2723588B1 (fr) * | 1994-08-12 | 1996-09-20 | Rhone Poulenc Rorer Sa | Adenovirus comprenant un gene codant pour la glutathion peroxydase |
JP2001507696A (ja) * | 1996-12-31 | 2001-06-12 | アンチオキシダント ファーマシューティカルズ コーポレーション | グルタチオンの医薬製剤およびその投与方法 |
US6270780B1 (en) * | 1997-07-25 | 2001-08-07 | Chesebrough-Pond's Usa Co., Division Of Conopco | Cosmetic compositions containing resveratrol |
JPH11124311A (ja) * | 1997-10-20 | 1999-05-11 | Shiseido Co Ltd | 光毒性抑制剤 |
ES2178405T3 (es) * | 1998-03-16 | 2002-12-16 | Somerset Pharmaceuticals Inc | Uso de selegilina o de desmetilselegilina para tratar heridas, quemaduras y lesiones cutaneas. |
CA2239205A1 (en) * | 1998-05-29 | 1999-11-29 | Gabrielle Boulianne | Extension of lifespan by overexpression of a gene that increases reactive oxygen metabolism |
JP3899210B2 (ja) * | 1999-08-27 | 2007-03-28 | 金印株式会社 | グルタチオン−s−トランスフエラーゼの活性誘導物質およびこれを含む食品 |
KR20030016202A (ko) * | 1999-11-24 | 2003-02-26 | 액세스 비지니스 그룹 인터내셔날 엘엘씨 | 국소성 피부 조성물 |
KR20020063914A (ko) | 1999-12-20 | 2002-08-05 | 코니스 프랑스, 에스.에이. | 화장용 및/또는 약학용 제제 |
JP2001316262A (ja) * | 2000-02-29 | 2001-11-13 | Santen Pharmaceut Co Ltd | 抗酸化剤 |
MXPA02010866A (es) * | 2000-05-05 | 2003-07-14 | Wisconsin Alumni Res Found | Composiciones y metodos para proteger celulas durante la quimioterapia y radioterapia contra el cancer. |
US6495170B1 (en) | 2000-08-16 | 2002-12-17 | N. V. Nutricia | Method of increasing the presence of glutathione in cells |
US6737441B2 (en) * | 2000-08-21 | 2004-05-18 | Jed W. Fahey | Treatment of helicobacter with isothiocyanates |
DE60234052D1 (de) * | 2001-12-18 | 2009-11-26 | Brassica Foundation For Chemop | Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen |
ATE511836T1 (de) * | 2005-04-29 | 2011-06-15 | Univ Johns Hopkins | Verfahren zur unterdrückung von durch uv-licht induzierter hautcarcinogenese |
-
2002
- 2002-12-18 DE DE60234052T patent/DE60234052D1/de not_active Expired - Lifetime
- 2002-12-18 JP JP2003552246A patent/JP2005536449A/ja active Pending
- 2002-12-18 WO PCT/US2002/040457 patent/WO2003051313A2/en active Application Filing
- 2002-12-18 AU AU2002357311A patent/AU2002357311A1/en not_active Abandoned
- 2002-12-18 EP EP09172558A patent/EP2138170A3/en not_active Withdrawn
- 2002-12-18 CN CN028281152A patent/CN1620304B/zh not_active Expired - Lifetime
- 2002-12-18 AT AT02805203T patent/ATE445405T1/de not_active IP Right Cessation
- 2002-12-18 CA CA2470583A patent/CA2470583C/en not_active Expired - Lifetime
- 2002-12-18 US US10/499,196 patent/US7407986B2/en not_active Expired - Lifetime
- 2002-12-18 EP EP20130181052 patent/EP2698153A1/en not_active Ceased
- 2002-12-18 EP EP02805203A patent/EP1474158B1/en not_active Expired - Lifetime
-
2008
- 2008-07-25 US US12/179,986 patent/US8303949B2/en active Active
-
2012
- 2012-11-06 US US13/670,161 patent/US8709406B2/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008016095A1 (fr) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
JP2011518860A (ja) * | 2008-04-29 | 2011-06-30 | ファーネクスト | ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物 |
WO2010084661A1 (ja) * | 2009-01-23 | 2010-07-29 | 金印株式会社 | イソチオシアネート類含有組成物、食品、食品素材、医薬品、化粧品および日用品雑貨類 |
JP2014532703A (ja) * | 2011-10-31 | 2014-12-08 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 自閉症の処置のための方法および組成物 |
WO2015002279A1 (ja) * | 2013-07-03 | 2015-01-08 | 味の素株式会社 | グルタチオン生成促進用組成物 |
Also Published As
Publication number | Publication date |
---|---|
US8303949B2 (en) | 2012-11-06 |
CA2470583A1 (en) | 2003-06-26 |
CN1620304B (zh) | 2010-06-23 |
ATE445405T1 (de) | 2009-10-15 |
EP2138170A3 (en) | 2010-06-23 |
AU2002357311A1 (en) | 2003-06-30 |
EP1474158A2 (en) | 2004-11-10 |
US20050063965A1 (en) | 2005-03-24 |
EP2138170A2 (en) | 2009-12-30 |
US7407986B2 (en) | 2008-08-05 |
CA2470583C (en) | 2011-03-15 |
EP1474158A4 (en) | 2006-09-13 |
US8709406B2 (en) | 2014-04-29 |
EP1474158B1 (en) | 2009-10-14 |
US20130157965A1 (en) | 2013-06-20 |
US20090017002A1 (en) | 2009-01-15 |
WO2003051313A3 (en) | 2003-10-16 |
CN1620304A (zh) | 2005-05-25 |
EP2698153A1 (en) | 2014-02-19 |
WO2003051313A2 (en) | 2003-06-26 |
DE60234052D1 (de) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005536449A (ja) | グルタチオンおよび第2相解毒酵素による酸化ストレス障害の予防および治療 | |
Özen et al. | Modulatory effect of Urtica dioica L.(Urticaceae) leaf extract on biotransformation enzyme systems, antioxidant enzymes, lactate dehydrogenase and lipid peroxidation in mice | |
US6812248B2 (en) | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes | |
Van Assche et al. | Leishmania–macrophage interactions: Insights into the redox biology | |
Conaway et al. | Inhibition of rat liver cytochrome P450 isozymes by isothiocyanates and their conjugates: a structure-activity relationship study | |
Nagaraj et al. | Effect of lupeol, a pentacyclic triterpene, on the lipid peroxidation and antioxidant status in rat kidney after chronic cadmium exposure | |
EP0963219B1 (en) | Manipulations of nitrosative and oxidative stress in the treatment of a disease | |
US6737441B2 (en) | Treatment of helicobacter with isothiocyanates | |
Ghyczy et al. | Electrophilic methyl groups present in the diet ameliorate pathological states induced by reductive and oxidative stress: a hypothesis | |
Martins et al. | Microcystin–LR exposure causes cardiorespiratory impairments and tissue oxidative damage in trahira, Hoplias malabaricus | |
Murray | Aminothiols | |
May | Selenium-based drug design: rationale and therapeutic potential | |
WO2019157245A1 (en) | Methods for treating mitochondrial disorders | |
US10065978B2 (en) | Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use | |
Simeonova et al. | Effects of myosmine on antioxidative defence in rat liver | |
Hillesheim et al. | Cytotoxicity of aromatic amines in rat liver and oxidative stress | |
RU2807600C1 (ru) | Антиоксидантный препарат для животных на основе водного раствора фуллерена С60, ресвератрола и альфа-липоевой кислоты | |
Djouhri-Bouktab et al. | Polyamines metabolism, toxicity and potent therapeutical use | |
Drukarch et al. | Parkinson's Disease 105 105 E. Ronken and GJM van Scharrenburg (Eds.) IOS Press, 2002 | |
Gibson | Fumaric acid esters | |
Jacoby | The role of nitric oxide and nitroxidative stress in amyotrophic lateral sclerosis | |
ES2357742T3 (es) | N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina o una sal farmacéuticamente aceptable de la misma para el uso en el tratamiento de la resistencia a la insulina. | |
Kopiuj et al. | Informacje o patencie | |
Geetha et al. | Influence of α-tocopherol on the antitumour potential and the toxicity of doxorubicin | |
Columbaro et al. | Treatment of FANCA Cells with Resveratrol and N-Acetylcysteine: A Comparative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090507 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090514 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090602 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090626 |